1/9/2024 0 Comments Ilibrary broski collins1-4 Given the significant variation in disease phenotype, monitoring of MM during surveillance and assessment of response to therapy has demanded incorporation of diverse clinical parameters to optimize accuracy in capturing disease activity. Multiple myeloma (MM) is a biologically heterogeneous disease, as exemplified by its variable genomics, secretory behavior, spatial heterogeneity, and extramedullary involvement. We conclude that an abnormal PET/CT scan near day 100 post-ASCT is predictive of shorter TTP and OS, with prognostic significance retained after adjusting for disease response and other prognostic variables in MM. The median OS in the PET + group was 46 months compared with 99 months in the PET − group ( P <. Among patients with abnormal day 100 PET findings (PET +), median TTP was 12.4 months vs 24 months among those with normal PET findings (PET −) ( P <. The median OS for the entire cohort was 61.5 months (95% confidence interval, 49-75) and the median TTP was 18.5 months (95% CI, 15.4-21.8). We retrospectively analyzed PET/CT scans in 229 MM patients receiving an autologous stem cell transplant (ASCT) near day 100, and correlated these findings with time to progression(TTP) and overall survival (OS) to assess the impact of day 100 PET/CT scan findings as an independent prognostic factor. We sought to corroborate these findings by examining the prognostic impact of PET/CT scanning in the posttransplant setting. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning has been shown to be predictive of patient outcomes throughout the disease course. Multiple myeloma (MM) is a heterogeneous disease that may be evaluated by a broad array of imaging and laboratory techniques to measure disease activity and predict prognosis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |